Technology

Kanyr identified a key PTP that negatively modulates immune cell activation. We developed proprietary small molecule inhibitors against this PTP and demonstrated that these inhibitors are able to boost immune cell functions against cancer cells.

 ImmunyrTM Technology uses ex-vivo-generated dendritic cells that are treated with proprietary PTP-inhibitors for the development of therapeutic cancer vaccines. ImmunyrTM boosts the dendritic cell's capacity to prime immune responses against cancers. Combined with potent tumor antigens, this technology paves the way for personalized anti-cancer vaccines.

 Kanyr also has proprietary on a small molecule lead compound inhibitor of the PRL phosphatases. all. These phosphatases are the most oncogenic phosphatases in the PTP family of enzymes.  All PRLs promote cell proliferation, tumour growth, invasion, and metastasis in over 90% of all cancers.